US-based medical device company CorNav has partnered with the Mayo Clinic to advance the treatment of ventricular tachycardia (VT) through a new know-how agreement.
The collaboration aims to enhance the development of CorNav’s CardioScout Epicardial Access System by leveraging Mayo Clinic’s expertise.
The CardioScout Epicardial Access System enables minimally invasive treatment of VT originating from the heart’s epicardial surface.
It is designed to address the limitations of current epicardial VT ablation methods, which rely on off-label catheters and two-dimensional imaging, potentially leading to complications.
The CardioScout system aims to provide a safer and more efficient solution.
CorNav founder and CEO James Fonger said: “The opportunity to collaborate with the Mayo Clinic is an extraordinary one.
The collaboration will substantially further our work in making epicardial VT ablation faster, safer, more effective and easier, ultimately improving outcomes for VT patients.”
The agreement follows an initial collaboration between CorNav and the Mayo Clinic, focused on developing solutions for congestive heart failure.
The expanded partnership seeks to address the unmet needs in VT treatment, which affects millions globally, including a significant number in the US.
Ventricular tachycardia is a critical cardiac rhythm disorder. Its current treatments involve using catheters not specifically designed for epicardial procedures.
The CardioScout Epicardial Access System uses a minimally invasive endoscopic platform to navigate the epicardial surface of the beating heart.
It accesses the heart through a small subxiphoid incision, using real-time, high-fidelity colour video imaging to ensure precise navigation and safer VT ablation.
The system features an endoscope with a flexible, segmented catheter body that conforms to the heart’s curvature.
Once positioned, the scope’s hood elevates to create a pericardial space, providing LED illumination and high-resolution imaging.
